Significance of CD66c expression in childhood acute lymphoblastic leukemia.
Upon analyzing 696 childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cases, we identified the characteristics of CD66c expression. In addition to the confirmation of strong correlation with BCR-ABL positivity and hyperdiploid, we further observed that CD66c is frequently expressed in CRLF2-positive (11/15, p<0.01 against chimeric gene-negative) as well as hypodiploid cases (3/4), whereas it is never expressed in ETV6-RUNX1, MLL-AF4, MLL-AF9, MLL-ENL, and E2A-PBX1-positive cases. Although the expression of CD66c itself is not directly linked to the prognosis, the accompanying genetic abnormalities are important prognostic factors for BCP-ALL, indicating the importance of CD66c expression in the initial diagnosis of BCP-ALL.
Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan. Electronic address: kiyokawa-n@ncchd.go.jp.
Nobutaka
N
Kiyokawa
Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan.
Kazutoshi
K
Iijima
Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan.
Osamu
O
Tomita
Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan; Department of Pediatrics, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Masashi
M
Miharu
Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan; Department of Pediatrics, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan.
Daisuke
D
Hasegawa
Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan.
Kenichiro
K
Kobayashi
Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo, Japan.
Hajime
H
Okita
Department of Transfusion Medicine, Medical Hospital, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan.
Michiko
M
Kajiwara
Department of Pediatrics, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Hiroyuki
H
Shimada
Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
Takeshi
T
Inukai
Division of Pediatric Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Atsushi
A
Makimoto
Department of Child Health, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Takashi
T
Fukushima
Department of Clinical Laboratory, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan.
Toru
T
Nanmoku
Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Saitama, Japan.
Katsuyoshi
K
Koh
Department of Pediatrics, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan.
Atsushi
A
Manabe
Department of Pediatrics, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan.
Akira
A
Kikuchi
Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
Kanji
K
Sugita
Clinical Research Center, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan.
Junichiro
J
Fujimoto
Department of Hematology-Oncology, Gunma Children's Medical Center, Shibukawa, Gunma, Japan.
Yasuhide
Y
Hayashi
Department of Pediatrics, Toho University Omori Medical Center, Ota-ku, Tokyo, Japan.
Akira
A
Ohara
D000293:Adolescent; D015703:Antigens, CD / Q000378:metabolism*; D015815:Cell Adhesion Molecules / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D050676:Core Binding Factor Alpha 2 Subunit / Q000235:genetics; D005260:Female; D005434:Flow Cytometry; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D058851:GPI-Linked Proteins / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D018398:Homeodomain Proteins / Q000235:genetics; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D051788:Myeloid-Lymphoid Leukemia Protein / Q000235:genetics; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D011379:Prognosis; D018121:Receptors, Cytokine / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000097764:ETS Translocation Variant 6 Protein
D015703:Antigens, CD; D015815:Cell Adhesion Molecules; D050676:Core Binding Factor Alpha 2 Subunit; D016044:Fusion Proteins, bcr-abl; D058851:GPI-Linked Proteins; D018398:Homeodomain Proteins; D051788:Myeloid-Lymphoid Leukemia Protein; D015514:Oncogene Proteins, Fusion; D018121:Receptors, Cytokine; C504117:CEACAM6 protein, human; C498762:CRLF2 protein, human; C113855:MLL-AF4 fusion protein, human; C474558:MLL-AF9 fusion protein, human; C425207:MLL-ENL oncoprotein, human; C102421:TEL-AML1 fusion protein; D000097764:ETS Translocation Variant 6 Protein; C089847:E2A-Pbx1 fusion protein
Acute lymphoblastic leukemia; CD66c; CRLF2, Flow cytometry; Genetic abnormality